OptiNose — Q1 2023 Earnings Presentation
19 slides from OptiNose's earnings presentation, May 11, 2023
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 1 , 2 0 2 3 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this
Slide 3: Key Takeaways
3 Key Takeaways Chronic sinusitis is a 10‐fold market opportunity for XHANCE Executing our strategy to prioritize the potential launch of XHANCE as the first‐ever FDA approved drug treatment for CS sNDA accepted for review by FDA – Target action date in December 2023
Slide 4: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis: New Growth Opportunities
4 Successful Development of XHANCE as the First and Only FDA‐approved Drug Treatment for Chronic Sinusitis Would Create Multiple New Growth Opportunities Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Mil
Slide 5: ReOpen Program Update
ReOpen Program Update
Slide 6: CS Supplemental NDA - Anticipated Next Steps
6 CS Supplemental NDA ‐ Anticipated Next Steps FDA accepted for review our supplemental new drug application (sNDA) in pursuit of a new indication PDUFA target action date is in December 2023 - Standard review period was applied
Slide 7: Q1 2023 Performance
Q1 2023 Performance
Slide 8: XHANCE Prescriptions
8 XHANCE Prescriptions XHANCE New Prescriptions increased 3% and Total Prescriptions increased 1% and HCPs who had more than 15 prescriptions filled by their patients decreased 1% from Q1 2022 to Q1 2023 29.5 30.4 Q1 '22 Q1 '23 (in thousands) XHANCE New Prescriptions 83.5 84.4 Q1 '22 Q1 '23 XHANCE T
Slide 9: Q1 2023 Financial Update
Q1 2023 Financial Update
Slide 10: Financial Review – First Quarter 2023
10 Financial Review – First Quarter 2023 SG&A plus R&D expenses decreased by ~$10M from Q1 2022 to Q1 2023 while Q1 2023 XHANCE Net Revenues exceeded previous guidance of approximately $10 million $34.1 $24.5 Q1 '22 Q1 '23 ($M) SG&A plus R&D Expenses $14.8 $11.8 Q1 '22 Q1 '23 ($M) Net Revenue Averag
Slide 11: 2023 Outlook
optinose_ ———— 2023 Outlook
Slide 12: Full Year 2023 Financial Guidance
12 Full Year 2023 Financial Guidance GAAP Operating Expenses (SG&A and R&D Expenses) ‒ Expected to be between $88 to $93 million; approximately $6 million of which represents stock‐based compensation ‒ Previously expected to be between $90 to $95 million; approximately $8 million of which represen
Slide 13: Closing Remarks
optinose_ ———— Closing Remarks
Slide 14: Key Takeaways
14 Key Takeaways Chronic sinusitis is a 10‐fold market opportunity for XHANCE Executing our strategy to prioritize the potential launch of XHANCE as the first‐ever FDA approved drug treatment for CS sNDA accepted for review by FDA – Target action date in December 2023
Slide 15: Investor Relations – Optinose Investor Contact
15 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267‐521‐0531 [email protected] As of March 31, 2023: – $83.9 million in cash – Debt: $130 million – 112 million common shares o/s – 46 million options, warrants & RSUs
Slide 16: Appendix - ReOpen Program Co-Primary Endpoints
Appendix ‐ ReOpen Program Co‐Primary Endpoints
Slide 17: Combined Symptom Score (Co-Primary Endpoint)
17 Combined Symptom Score (Co‐Primary Endpoint) Improvement in combined symptoms with XHANCE; Consistent with NAVIGATE I and II 1 ‐0.81 ‐1.54* ‐1.74‡ ‐2.0 ‐1.8 ‐1.6 ‐1.4 ‐1.2 ‐1.0 ‐0.8 ‐0.6 ‐0.4 ‐0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS‐placebo BID OPN‐375
Slide 18: Average of Percentages of Opacified Volume (Ethmoid and Maxillary)
18 Average of Percentages of Opacified Volume (Ethmoid and Maxillary) Objective Evidence of Effect in Sinus Cavities by CT Scan; Co‐Primary Endpoint 1.19 ‐7.00‡ ‐5.14♰ ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 2 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to
Slide 19: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 1 , 2 0 2 3